Fallopian Tube Cancer Market - Size,
share, Outlook, and Opportunity Analysis,
2018-2026
Cells in the body divide and grow to replace damaged and old cells. Cell growth is highly
regulated and when sufficient amount of cells are produced to replace the old ones, the division
of normal cells is stopped. Regulation error in the cell division process can cause cells to
continually divide in an uncontrollable manner, which leads to the development of tumor.
Fallopian tubes are also known as oviducts, which are a pair of narrow tubes that transport ova
(eggs) to the uterus. Abnormal growth of malignant cells in one or both fallopian tubes in
women can cause fallopian tube cancer. Majority of fallopian tube cancer are of papillary serous
adenocarcinomas type, the other two types of fallopian tube cancer are very rare such as
sarcoma, which affects the muscular part of the fallopian tube and transitional cell found in the
fallopian tube lining, and metastasis that spreads cancer cells to other parts of the body. The
symptoms of ovarian cancer are similar to that of fallopian tube cancer, which include
abdominal pain, watery discharge that may contain blood, vaginal bleeding, and swollen
abdomen. Tests for diagnosis of fallopian tube cancer include CA125 blood test, pelvic exam,
ultrasound, and CT scan. Some of the recommended treatment options for fallopian tube cancer
are open surgery treatment, which involves the removal of the uterus through an incision in the
abdomen and chemotherapy treatment, using drugs to kill cancer cells, which may be
prescribed pre- and post-surgery.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/1826
Fallopian Tube Cancer Market Dynamics:
Increasing development of treatments is expected to boost growth of the fallopian tube cancer
market. For instance, In 2018 Rucaparib, a poly ADP-ribose polymerase (PARP) inhibitor,
developed by Clovis Oncology Inc. received FDA approval for the maintenance treatment of
recurrent fallopian tube cancer, ovarian cancer or primary peritoneal cancer. Moreover,
increasing prevalence of cancer-related diseases and genetic disorders are factors responsible for
fallopian tube cancer market growth. According to 2018 statistics by the Foundation for